🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🌟 Huge congratulations to Nazli Dizman, Rafeh Naqash, MD, Amin Nassar, MD, Charles Jiang MD, MPH and all the incredible recipients of this year’s Conquer Cancer awards! #ASCO25 ASCO ASCO TECAG Conquer Cancer, the ASCO Foundation Hem-Onc Fellows Network OncoAlert #MedTwitter #IMGCoP

Any OS or PFS benefit in small cell is a win in my book, but … the grade 3/4 AEs… What does this teach me? - low threshold for dose modification of lurbi post platinum etop… - more frequent check ins #LCSM

Love these #protips from Charu Aggarwal, MD, MPH, FASCO. Simple and doable and is a great way to network and get immersed in the science! #ASCO25 ASCO

Congratulations to the newly elected IASLC board members - so many great candidates this year - can't wait to see what they have in store! Alex A. Adjei Triparna Sen (Sen-Lab) Mary Pasquinelli Isabelle Opitz Hidehito HORINOUCHI Clarissa Baldotto Narjust Florez, MD, FASCO

Traveling w/ mixed emotions to @asco #asco25 this yr. Celebrating science & the yrs of dedication, work, & patient contributions to cancer clinical trials. But science itself is under attack — defunding of preclinical discovery work will end up slowing our clinical advances. 1/n

🔥🚨OncoAlert Hot Off The Press Big #NewsRelease by Summit Therapeutics in time with #ASCO25 Results from the #HARMONi Phase III global trial evaluating: #Ivonescimab + #Chemo vs #Chemo in pts with advanced #EGFR+ #NSCLC after progression on 3rd gen TKI: ⭐️Statistically significant &

🎖️Day 2 of #ASCO25 at ASCO TECAG lounge with a full agenda! ASCO ✨Come join us for excellent panels, networking opportunities, one-on-one mentorship and to relax, recharge and grab snacks & coffee! Agenda 👉cdn.bfldr.com/KOIHB2Q3/as/7c… #MedEd Rami Manochakian MD, FASCO Cancer Education Nazli Dizman

BN-39643 represents the newest concept of EGFR TKI, higher potency than osimertinib, CNS penetration, covering classical, C797S, PACC, and ex20 mutations, so it prevents all EGFR dependent resistance.

Come through to hear our perspectives on finding your first job! ASCO TECAG #FlorezLab

Yesterday evening, before heading to #MiamiNights, had the chance to be part of an incredibly engaging and insightful OncLive.com workshop discussing key #LungCancer abstracts from #ASCO25 — with expert moderation and mentorship from Eric K. Singhi, MD! 💡🫁

The new tumour board? ⁦Nature Cancer⁩ - multimodel AI agent integrates patient data using GPT-4, MSI/KRAS/BRAF slides, radiologic images, OncoKB/PubMed/Google - AI agent makes correct clinical decision in 91% cases ⁦Jakob Nikolas Kather⁩ ⁦OncoAlert⁩ nature.com/articles/s4301…

Now that Taletrectinib is approved by @usfda for metastatic NSCLC Check out the comparison of data for three ROS-1 inhibitors, entrectinib , repotrectinib and Taletrectinib. Useful for quick summary of data for all 3 . Rami Manochakian MD, FASCO Cancer Education OncoAlert Oncology Brothers Kate Sears

🚨🎙️Just Published: Our piece on Shared Decision Making (SDM) for Personalized #LungCancer Care. In this article, we highlight the scope and need for Purposeful SDM: ➡️ SDM captures the collaborative conversations between patients and clinicians—whether it’s navigating tough

Updated Ph II PHAROS Trial Encorafenib + Binimetinib BRAF V600E+ mNSCLC JTO & JTO CRR: - 59pts 1L, 39pts 2L - 1L: ORR 75%, mDOR 40m, 3yr OS 53% - 2L: ORR 46%, mDOR 16.7m, 3yr OS 29% A good option, particularly upfront Gʀᴇɢᴏʀʏ Rɪᴇʟʏ OncoAlert #LcSM jto.org/article/S1556-…

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing